DAX6.050-3,4%  Dow12.119-2,2%  Euro1,24320,6% 
ESt502.069-2,4%  Nas2.748-2,8%  Öl98,82-2,8% 
TDax730,9-2,7%  Nikkei8.440-1,2%  Gold1.6264,2% 
Home > Aktien > Spectranetics Aktie > Nachrichten zu Spectranetics

Spectranetics Aktie [WKN: 883391 / ISIN: US84760C1071]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyHome
OrderbuchRealtime StuttgartRSS Feed im ForumFondsSenden
HistorischRealtime PushmyNews neu IR-DatenAnleihen
handeln

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur Spectranetics Corp.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur Spectranetics Corp.

18.02.10Spectranetics Reports Record Fourth Quarter Revenue, Up 11% to $29.7 Million
09.02.10Spectranetics to Hold 2009 Fourth Quarter Financial Results Conference Call on February 18
02.02.10Journal of American College of Cardiology Publishes Study Demonstrating Safety & Effectiveness of Laser Assisted Lead Removal
13.01.10Published Study Demonstrates Effectiveness of Spectranetics Turbo-Booster® for Peripheral Artery Disease
29.12.09Spectranetics Announces Resolution of Federal Investigation
03.12.09Spectranetics Announces FDA Clearance of VisiSheath™ Dilator Sheath, New Lead Management Device
04.11.09Spectranetics to Present at the Canaccord Adams 3rd Annual Cardiovascular Conference on November 10
28.10.09Spectranetics Reports Third Quarter Revenue Up 7% to $28.8 Million
21.10.09Spectranetics to Hold 2009 Third Quarter Financial Results Conference Call on October 28
29.09.09Spectranetics Submits 510(k) Application to Food and Drug Administration Seeking Clearance for the Treatment of In-Stent Restenosis in the Legs
29.07.09Spectranetics to Present at Canaccord Adams’ 29th Annual Global Growth Conference on August 12
23.07.09Spectranetics Reports Second Quarter Revenue of $29 Million
16.07.09Spectranetics to Hold 2009 Second Quarter Financial Results Conference Call on July 23
15.07.09Spectranetics Announces First Human Uses of Turbo-Tandem™ System
09.07.09Spectranetics Announces FDA Clearance to Market Turbo-Tandem™ System
25.06.09Spectranetics Names Jason Hein Senior VP, Sales, Marketing and Product Development
23.06.09Spectranetics Receives CE Mark Approval for ThromCat®XT
06.05.09Spectranetics Reports 15% Revenue Growth in First Quarter 2009
05.05.09Spectranetics Makes Pre-IDE Submission to FDA for the Treatment of In-Stent Restenosis in the Legs
04.05.09Data Shows Laser Assisted Lead Removal Effective: Spectranetics Releases Data from LExICon Study
27.04.09Spectranetics to Hold 2009 First Quarter Financial Results Conference Call on May 6
25.02.09Spectranetics Appoints William Jennings and Anne Melissa Dowling as Independent Directors
19.02.09Spectranetics Reports Financial Results for Fourth Quarter and Full Year 2008
12.02.09Spectranetics to Hold 2008 Fourth Quarter Financial Results Conference Call on February 19
29.01.09Spectranetics Announces Executive Appointments to Further Enhance Compliance Programs
21.01.09Spectranetics Reports on 12-Month CELLO Data at LINC Meeting in Leipzig, Germany
08.01.09Spectranetics Reports Preliminary Revenue for Fourth Quarter and Full-Year 2008
18.12.08Spectranetics’ International, B.V. Achieves New Sales Milestone
15.12.08Spectranetics Cross-Pilot Product Receives FDA Clearance
11.12.08Spectranetics Quick-Cross Extreme Product Line Receives FDA Clearance
06.11.08Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Files Class Action Lawsuit Against The Spectranetics Corp.
03.11.08Spectranetics Receives NASDAQ Notice
29.10.08Spectranetics Third Quarter Revenue up 26% to $26.8 Million
29.10.08Spectranetics Third Quarter Revenue up 26% to $26.8 Million
24.10.08Spectranetics to Hold 2008 Third Quarter Financial Results Conference Call on October 29
22.10.08Spectranetics Appoints Company Chairman, Emile J. Geisenheimer, as President and Chief Executive Officer
22.10.08Spectranetics Appoints Company Chairman, Emile J. Geisenheimer, as President and Chief Executive Officer
25.09.08Izard Nobel LLP Announces Class Action Lawsuit Against The Spectranetics Corporation
25.09.08Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against The Spectranetics Corporation
25.09.08Spectranetics Announces Securities Lawsuits and Commission Inquiry

Anzeige

ANZEIGE

Seite: 12
Wie bewerten Sie diese Seite?
schlecht sehr gut
Problem mit dieser Seite?
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2012 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon